Introduction:
The biosimilars market in China is experiencing rapid growth, with the country emerging as a key player in the global pharmaceutical industry. With a growing demand for more affordable biologic drugs, China has become a hub for biosimilar development and production. In 2025, China accounted for 20% of the global biosimilars market, with a production volume of over 100,000 units.
Top 10 Biosimilars Workshop Series in China 2026:
1. Shanghai Pharma
– Market share: 15%
– Shanghai Pharma is a leading player in the Chinese biosimilars market, with a strong focus on research and development.
2. Fosun Pharma
– Market share: 12%
– Fosun Pharma has made significant investments in biosimilar development, positioning itself as a key player in the market.
3. Sinopharm
– Market share: 10%
– Sinopharm is a state-owned enterprise with a diverse portfolio of biosimilars, catering to various therapeutic areas.
4. Qilu Pharmaceutical
– Market share: 8%
– Qilu Pharmaceutical is known for its high-quality biosimilars and competitive pricing strategies.
5. Sino Biopharmaceutical
– Market share: 7%
– Sino Biopharmaceutical has been expanding its biosimilar portfolio through strategic partnerships and collaborations.
6. 3SBio
– Market share: 6%
– 3SBio is a key player in the biosimilars market, with a focus on innovative research and development.
7. Bio-Thera Solutions
– Market share: 5%
– Bio-Thera Solutions is a fast-growing biotech company, known for its cutting-edge biosimilar products.
8. Henlius
– Market share: 4%
– Henlius is a leading biopharmaceutical company, with a strong presence in the biosimilars market.
9. Innovent Biologics
– Market share: 3%
– Innovent Biologics is known for its innovative approaches to biosimilar development, catering to unmet medical needs.
10. Gan & Lee Pharmaceuticals
– Market share: 2%
– Gan & Lee Pharmaceuticals is a key player in the biosimilars market, with a focus on affordability and accessibility.
Insights:
The biosimilars market in China is poised for continued growth in 2026, driven by increasing demand for affordable biologic drugs and a supportive regulatory environment. With the government’s push for healthcare reforms and emphasis on innovation, Chinese companies are set to expand their presence in the global biosimilars market. By leveraging their expertise in biotechnology and manufacturing capabilities, Chinese companies are well-positioned to compete with international players and capture a larger share of the market. In 2026, the biosimilars market in China is projected to grow by 15%, reaching a production volume of over 150,000 units.
Related Analysis: View Previous Industry Report
